cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1491Research ArticleМНЕНИЕ ПО ПРОБЛЕМЕOPINION ON A PROBLEMНовые ориентиры в контроле артериальной гипертонии у больных ишемической болезнью сердца на основе рекомендаций по лечению артериальной гипертонии ЕОАГ/ЕОК 2007гNew targets for arterial hypertension control in patients with coronary heart disease: ESH/ESC guidelines on arterial hypertension management, 2007КарповЮ. А.KarpovYu. A.karpov.cardio@mtu-net.ruФГУ Российский кардиологический научно&производственный комплекс Росмедтехнологии, МоскваRussian Cardiology Scientific and Clinical Complex, Federal Agency on High Medical Technologies, Moscow200701011970777883Copyright © Карпов Ю.А., 19701970Карпов Ю.А.Karpov Y.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1491

Повышенное артериальное давление (АД) – один из основных независимых факторов риска развития сердечно-сосудистых осложнений. В клинической практике сочетание ишемической болезни сердца (ИБС) с артериальной гипертонией (АГ) существенно увеличивает риск неблагоприятного исхода и встречается часто. В июне 2007г были представлены новые рекомендации ЕОАГ/ЕОК по лечению АГ, в которых установлен новый целевой уровень АД для больных АГ в сочетании с ИБС < 130/80 мм рт.ст. Достижение нового целевого уровня АД у больных АГ в сочетании с ИБС при проведении всего комплекса превентивной терапии гарантирует дальнейшее улучшение прогноза.

Elevated blood pressure (BP) is one of the main independent risk factors for cardiovascular complication development. In clinical practice, the combination of coronary heart disease (CHD) and arterial hypertension (AH), increasing adverse outcome risk, is highly prevalent. In June 2007, new guidelines on AH management, were presented by ESH and ESC, providing a new target level of BP for CHD and AH patients: <130.80 mm Hg. The achievement of this new target level, as a part of complex preventive measures, guarantees improved prognosis in CHD and AH individuals.

артериальная гипертонияишемическая болезнь сердцацелевой уровень артериального давленияarterial hypertensioncoronary heart diseasetarget blood pressure levelReferencesRosendorff C. Treatment of hypertension patients with ischemic heart disease. In: Izzo JL Jr, Black HR, eds: Hypertension Primer: The essentials of high blood pressure: basic science, population science, and clinical management. Philadelphia, PA: Lippincott Williams - Wilkins 2003; 456–9.Rosendorff C. Treatment of hypertension patients with ischemic heart disease. In: Izzo JL Jr, Black HR, eds: Hypertension Primer: The essentials of high blood pressure: basic science, population science, and clinical management. Philadelphia, PA: Lippincott Williams - Wilkins 2003; 456–9.Под редакцией акад. ЕИ.Чазова. Болезни сердца и сосудов. Руководство для врачей. Москва «Медицина» 1992; 2: 5–42.Под редакцией акад. ЕИ.Чазова. Болезни сердца и сосудов. Руководство для врачей. Москва «Медицина» 1992; 2: 5–42.Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial Group. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease: over-all findings and differences by age for 316,099 white men. Arch Intern Med 1992; 152: 56–64.Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial Group. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease: over-all findings and differences by age for 316,099 white men. Arch Intern Med 1992; 152: 56–64.2003 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension. Guidelines Committee. J Hypertens 2003; 21 (6): 1011–53.2003 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension. Guidelines Committee. J Hypertens 2003; 21 (6): 1011–53.Карпов ЮА. Ишемическая болезнь сердца в сочетании с артериальной гипертонией: особенности течения и выбор терапии. Кардиология 2005; 12: 93–8.Карпов ЮА. Ишемическая болезнь сердца в сочетании с артериальной гипертонией: особенности течения и выбор терапии. Кардиология 2005; 12: 93–8.Шальнова СА., Деев АД., Карпов ЮА. от имени участников программы ПРЕМЬЕРА. Артериальная гипертония и ИБС в амбулаторной практике врача кардиолога. Кардиоваск тер профил 2006; 5(2): 73–80.Шальнова СА., Деев АД., Карпов ЮА. от имени участников программы ПРЕМЬЕРА. Артериальная гипертония и ИБС в амбулаторной практике врача кардиолога. Кардиоваск тер профил 2006; 5(2): 73–80.Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in out-patients with atherothrombosis. JAMA 2006; 295: 180–9.Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in out-patients with atherothrombosis. JAMA 2006; 295: 180–9.Карпов ЮА., Шальнова СА., Деев АД. от имени участников программы ПРЕМЬЕРА. Престариум у больных с артериальной гипертонией и ишемической болезнью сердца (или факторами риска) – безопасное достижение целевого уровня артериального давления (ПРЕМЬЕРА): результаты клинического этапа национальной программы. Кардиология 2006; 6: 32–8.Карпов ЮА., Шальнова СА., Деев АД. от имени участников программы ПРЕМЬЕРА. Престариум у больных с артериальной гипертонией и ишемической болезнью сердца (или факторами риска) – безопасное достижение целевого уровня артериального давления (ПРЕМЬЕРА): результаты клинического этапа национальной программы. Кардиология 2006; 6: 32–8.The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Guidelines on the management of stable angina pectoris: executive summary. Eur Heart J 2006; 27: 1341–81.The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Guidelines on the management of stable angina pectoris: executive summary. Eur Heart J 2006; 27: 1341–81.Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2: Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827–38.Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2: Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827–38.Blood Pressure Lowering Treatment Trialists Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet 2003; 362: 1527–45.Blood Pressure Lowering Treatment Trialists Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet 2003; 362: 1527–45.Lindholm LH, Carlberg B, Samuelsson O. Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545–53.Lindholm LH, Carlberg B, Samuelsson O. Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545–53.The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiolody. 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105–87.The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiolody. 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105–87.Sever PS, Dahlof B, Poulter NR, et al., for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895–906.Sever PS, Dahlof B, Poulter NR, et al., for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895–906.Pepine C, Handberg EM, Cooper-deHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805–16.Pepine C, Handberg EM, Cooper-deHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805–16.The ALLHAT Officers and Coordinators. Major outcomes in high-risk hypertensive patients randomized to ACE inhibitor or calcium channel blocker vs diuretic (ALLHAT). JAMA 2002; 288: 2981–97.The ALLHAT Officers and Coordinators. Major outcomes in high-risk hypertensive patients randomized to ACE inhibitor or calcium channel blocker vs diuretic (ALLHAT). JAMA 2002; 288: 2981–97.Poole-Wilson PA, Lubsen J, Kirvan B-A, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomized controlled trial. Lancet 2004; 364: 849–57.Poole-Wilson PA, Lubsen J, Kirvan B-A, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomized controlled trial. Lancet 2004; 364: 849–57.Lubsen J, Wagener G, Kirvan B-A, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. J Hypertens 2005; 23: 641–8.Lubsen J, Wagener G, Kirvan B-A, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. J Hypertens 2005; 23: 641–8.Nissen SE, Tuscu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary artery disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217–26.Nissen SE, Tuscu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary artery disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217–26.The HOPE Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. N Engl J Med 2000; 342: 145–53.The HOPE Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. N Engl J Med 2000; 342: 145–53.Gianni M, Bosch J, Pogue J, et al. Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients. Eur Heart J 2007; 28: 1382–8.Gianni M, Bosch J, Pogue J, et al. Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients. Eur Heart J 2007; 28: 1382–8.The EUROPA investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362; 782–8.The EUROPA investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362; 782–8.Ceconi C, Fox K, Remme WJ, et al. Effect of perindopril in patients with stable coronary artery disease: results of the PERTINENT sub-study (abstr no.3665). J Hypertens 2005; (23 Suppl 2): 274.Ceconi C, Fox K, Remme WJ, et al. Effect of perindopril in patients with stable coronary artery disease: results of the PERTINENT sub-study (abstr no.3665). J Hypertens 2005; (23 Suppl 2): 274.Pepine CJ, Kowey PR, Kupfer S, et al. INVEST Investigators. Predictors of adverse outcome among patients with hypertension and coronary artery disease. JACC 2006; 47: 547–51.Pepine CJ, Kowey PR, Kupfer S, et al. INVEST Investigators. Predictors of adverse outcome among patients with hypertension and coronary artery disease. JACC 2006; 47: 547–51.Curran MP, McCormack PL, Simpson D. Perindopril. A review of its use in patients with and at risk of developing coronary artery disease. Drugs 2006; 66(2): 235–55.Curran MP, McCormack PL, Simpson D. Perindopril. A review of its use in patients with and at risk of developing coronary artery disease. Drugs 2006; 66(2): 235–55.Карпов ЮА, Деев АД от имени врачей – участников исследования ПРИВИЛЕГИЯ. Исследование ПРИВИЛЕГИЯ – ПРестарИум В леченИи артериаЛьной гипЕртонии: антиГИпертензивнаЯ эффективность и безопасность в сравнении с эналаприлом. Кардиология 2007 (принята в печать).Карпов ЮА, Деев АД от имени врачей – участников исследования ПРИВИЛЕГИЯ. Исследование ПРИВИЛЕГИЯ – ПРестарИум В леченИи артериаЛьной гипЕртонии: антиГИпертензивнаЯ эффективность и безопасность в сравнении с эналаприлом. Кардиология 2007 (принята в печать).Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356.Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356.

The authors declare that there are no conflicts of interest present.